Table 1.
Clinical Characteristics of Stage IV LCNEC Patients with or without Immunotherapy
| Immunotherapy | Total | P value | ||
|---|---|---|---|---|
| Yes | No | |||
| Total | 37 (100%) | 624 (100%) | 661 (100%) | |
| Age | ||||
| <70 | 25 (68%) | 398 (64%) | 423 (64%) | 0.641 |
| 70+ | 12 (32%) | 226 (36%) | 238 (36%) | |
| Sex | ||||
| Male | 23 (62%) | 337 (54%) | 360 (54%) | 0.333 |
| Female | 14 (38%) | 287 (46%) | 301 (46%) | |
| Race | ||||
| Whites and others | 37 (100%) | 624 (100%) | 661 (100%) | 0.943 |
| Insurance status | ||||
| Uninsured | 0 (0%) | 19 (3%) | 19 (3%) | 0.281 |
| Others | 37 (100%) | 605 (97%) | 642 (97%) | |
| Institution | ||||
| Academic | 17 (46%) | 201 (32%) | 218 (33%) | 0.084 |
| Others | 20 (54%) | 423 (68%) | 443 (67%) | |
| Charlson-Deyo score | ||||
| 0-1 and 2-3+ | 37 (100%) | 624 (100%) | 661 (100%) | 0.541 |
| Brain metastasis | ||||
| Yes and No | 37 (100%) | 624 (100%) | 661 (100%) | 0.127 |
| Liver metastasis | ||||
| Yes | 10 (27%) | 170 (27%) | 180 (27%) | 0.977 |
| No | 27 (73%) | 454 (73%) | 481 (73%) | |
| Surgery for primary lesion | ||||
| Yes | 10 (3%) | 170 (6%) | 180 (27%) | 0.43 |
| No | 27 (97%) | 454 (94%) | 481 (73%) | |
| Radiation | ||||
| Yes | 17 (46%) | 324 (52%) | 341 (52%) | 0.48 |
| No | 20 (54%) | 300 (48%) | 320 (48%) | |
| Chemotherapy | ||||
| Yes and No | 37 (100%) | 624 (100%) | 661 (100%) | 0.0008 |
Note: Due to NCDB agreement, cells with less than 10 cases in Race, Charlson-Deyo score, Brain metastasis and Chemotherapy were combined with other opposing cells.